Publications by authors named "H J Conter"

Claim this Profile
M
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.
Adam M Brufsky, Kent F Hoskins, Henry J Conter, Pond Kelemen, Mehran Habibi

JNCI Cancer Spectr· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.
Evan Y Yu, Cristiano Ferrario, Mark D Linch, Michael Stoeckle, Brigitte Laguerre, Henry J Conter

Eur Urol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.
Arif Ali Awan, Carol Stober, Gregory R Pond, Igor Machado, Lucas Clemons, Henry Conter

Breast Cancer Res Treat· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Scoping Review of the Current Knowledge of the Social Determinants of Health and Infectious Diseases (Specifically COVID-19, Tuberculosis, and H1N1 Influenza) in Canadian Arctic Indigenous Communities.
Fariba Kolahdooz, Se Lim Jang, Sarah Deck, David Ilkiw, Gertrude Omoro, Henry J Conter

Int J Environ Res Public Health· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Evan Y Yu, William R Berry, Howard Gurney, Margitta Retz, Henry J Conter

Eur Urol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis